Dr Eng on the Ongoing Investigation of Fruquintinib in Relapsed/Refractory mCRC

Cathy Eng, MD, FACP, FASCO, discusses the ongoing investigation of fruquintinib in patients with relapsed/refractory metastatic colorectal cancer.

Related Keywords

Davidh Johnson ,Cathy Eng ,Gastrointestinal Gi Cancer Research Program ,Vanderbilt Ingram Cancer Center ,Swog Gi Committee ,Vanderbilt Ingram Cancer Center Young Adult Cancers Initiative ,Medical Oncology ,Cancer Research Program ,Clinical Updates In Colorectal Cancer ,Onclive Tv ,Metastatic Colorectal Cancer ,